Document is current
Any future updates will be listed below
-
Authors
Mück, Anna https://orcid.org/0009-0005-6943-5867
Pfeuffer, Steffen
Mir, Lara
Genau, Sonja
Emde, Julia
Olbricht, Linus
Omar, Omar A.
Blaes, Franz
Best, Christoph
Huttner, Hagen B.
Krämer, Heidrun H.
-
Funding
Funding for this research was provided by:
Justus-Liebig-Universität Gießen
- License Information
-
More Information
Article History
Received: 8 March 2024
Revised: 24 May 2024
Accepted: 26 May 2024
First Online: 5 June 2024
Declarations
:
: A.M: no conflicts of interest. S.P.: received travel grants from Sanofi, Roche Pharma and Merck Healthcare, lecturing honoraria and consulting fees from Sanofi, Mylan, Novartis, Merck Healthcare, Biogen, Hexal, Alexion, Roche Pharma, and research support from Diamed, Merck, Biogen, Novartis and the German Multiple Sclerosis Society North-Rhine-Westphalia. L.M.: no conflicts of interest. S.G.: no conflicts of interest. J.E.: no conflicts of interest. L.O.: no conflicts of interest. O.A.O: no conflicts of interest. C.B.: received lecturing honoraria and consulting fees from Novartis, Bayer and Portola. F.B. received travel grants from alexion, lecturing honoraria and consulting fees from UCB, argenX and Grifols. H.B.H.: received personal honoraria and/or unrestricted research grants from Portola Pharmaceuticals, Boehringer Ingelheim, Daiichi Sanyko, Bayer AG, Novartis, Astrazeneca and CSL Behring outside the submitted work. H.H.K.: received travel grants Alexion and Grifols, lecturing honoraria and consulting fees from Sanofi, Alexion, Roche Pharma, Argenx, UCB and research support from Roche.
